Clinical Trials
21 trialsNCT06290622 2025-05-06
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT06003179 2024-11-12
LOKI
University Health Network, Toronto
Phase 1 Withdrawn
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT05176691 2023-02-21
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
Phase 1 Withdrawn
NCT05228249 2023-01-13
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT04974996 2022-03-29
LOTIS-8
ADC Therapeutics S.A.
Phase 1 Withdrawn
NCT00004114 2020-07-31
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04279938 2020-02-21
A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL
Royal Marsden NHS Foundation Trust
Phase 1 Withdrawn
NCT02274506 2020-01-22
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03349346 2018-12-11
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Gilead Sciences
Phase 1 Withdrawn
NCT02595242 2017-05-23
Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Withdrawn
NCT02780830 2016-09-15
INHIBITOR
AstraZeneca
Phase 1 Withdrawn
NCT00002956 2016-03-21
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02532192 2016-01-06
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00024115 2015-04-28
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT02238522 2014-11-13
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Zenith Epigenetics
Phase 1 Withdrawn
NCT00521261 2014-03-05
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn